Lion TCR, a Singapore-headquartered clinical-stage biotech company, reported significantly higher losses for the year ended December 31, 2021, on zero revenues as it continued to work on clinical trials of its chronic Hepatitis B treatments.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
